Global /South Korea /Healthcare /Drug Manufacturers - General /061250

Hwail Pharmaceutical Co.,Ltd.

061250

• KRX: 061250 • Delayed

9,430KRW -2.2%

6.21 USD

As of 14 June 2026, Hwail Pharmaceutical Co.,Ltd. has a market cap of $52.19M USD, ranking #30293 globally and #1708 in South Korea. It ranks #2739 in the Healthcare sector, and #963 in the Drug Manufacturers - General industry.

Global Rank

30293

Country Rank

1708

Sector Rank

2739

Industry Rank

963

Key Stats

Market Cap

$52.19MUSD

79.38B KRW

Revenue (TTM)

$70.93MUSD

107.87B KRW

EBITDA (TTM)

$3.43MUSD

5.2B KRW

Net Income (TTM)

$1.27MUSD

1.92B KRW

EBITDA Margin

4.8%

Profit Margin

1.8%

PE Ratio

19.9

PS Ratio

0.7

PB Ratio

0.8

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Joung-Kyu Lee open_in_new

Employees

130

Founded

1974

Website

hwail.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.2%	-8%	-6.7%	-18%	-17%	-17%	-10%	-57%	-81%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	061250 화일약품(주) ISIN: KR7061250007 Shares Out.: Shares Outstanding: 8.418M¹ Shares Float: 7.308M² TV: TradingView: KRX: 061250 SA: Stock Analysis: KRX: 061250 YF: Yahoo Finance: 061250.KS GF: Google Finance: KRX: 061250 BA: Barron's: 061250 MS: Morningstar: XKRX: 061250	9,430 KRW	TV: TradingView: KRX: 061250 SA: Stock Analysis: KRX: 061250 YF: Yahoo Finance: 061250.KS GF: Google Finance: KRX: 061250 BA: Barron's: 061250 MS: Morningstar: XKRX: 061250

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Hwail Pharmaceutical Co.,Ltd.

Hwail Pharmaceutical Co.,Ltd. develops pharmaceutical raw materials in South Korea. It provides raw drug products, finished drug products, and functional health food raw material business. The company was founded in 1974 and is headquartered in Seongnam-si, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.15B 13.91T KRW 17K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.77B 10.3T KRW 13K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.24B 7.97T KRW 10K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.96B 7.55T KRW 9K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.55B 6.92T KRW 9K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.44B 6.76T KRW 8K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 1M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 691K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 616K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 553K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 526K%	20.5	Switzerland

chevron_leftBack